Bioenvision news from FierceBiotech
NewsGenzyme lands $345M acquisition of Bioenvision
Genzyme is laying claim to the keys to Bioenvision after winning shareholders' approval of the $345 million buyout. SCO Capital Partners, which owns 13 percent of Bioenvision, had Read more...
| Press ReleasesPRESS RELEASE: Bioenvision Shareholders Approve Acquisition by Genzyme Corporation Bioenvision Shareholders Approve Acquisition by Genzyme Corporation Genzyme Corporation and Bioenvision announced this afternoon that Bioenvision stockholders have voted to approve the acquisition Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets